Results showed that in addition to the remarkable anti-tumor effects of the PCSK9 inhibitor (P = 0.0001) or the OVA long peptide vaccine (P < 0.0001) alone, synergistic tumor-repressing effects were achieved by the combination of PCSK9 inhibitor with OVA-II vaccine than either PCSK9 inhibitor (P < 0.0001) or OVA-II peptide alone(P = 0.0226) (Fig. 6B, C, D). Here, PCSK9 is linked to neoplasm.